Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| THERAPEUTIC GONADOTROPIN | ? unclear | Mechanistic | DGIdb | |
| ETHINYL ESTRADIOL | ? unclear | Mechanistic | DGIdb | |
| DIETHYLSTILBESTROL | ? unclear | Mechanistic | DGIdb | |
| CHORIOGONADOTROPIN ALFA | ? unclear | Mechanistic | DGIdb | |
| TESTOSTERONE | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC HORMONE | ? unclear | Mechanistic | DGIdb | |
| TRETINOIN | ? unclear | Mechanistic | DGIdb |
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| AMI-1 | ? unclear | Mechanistic | DGIdb | |
| DIBEKACIN | ? unclear | Mechanistic | DGIdb | |
| CARBONYL CYANIDE M-CHLOROPHENYLHYDRAZONE | ? unclear | Mechanistic | DGIdb | |
| TRIPARANOL | ? unclear | Mechanistic | DGIdb | |
| DODINE | ? unclear | Mechanistic | DGIdb | |
| TANNIC ACID | ? unclear | Mechanistic | DGIdb | |
| DEFLAZACORT | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1235854 | ? unclear | Mechanistic | DGIdb | |
| ERGONOVINE | ? unclear | Mechanistic | DGIdb | |
| AMPEROZIDE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| ATROPINE METHYLBROMIDE | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL VALERATE | ? unclear | Mechanistic | DGIdb | |
| BERBERINE CHLORIDE | ? unclear | Mechanistic | DGIdb | |
| NITRALIN | ? unclear | Mechanistic | DGIdb | |
| DEVAZEPIDE | ? unclear | Mechanistic | DGIdb | |
| MOCLOBEMIDE | ? unclear | Mechanistic | DGIdb | |
| GLPG0492 | ~ modulates | Mechanistic | DGIdb | |
| DEUTENZALUTAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PRUXELUTAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| HEPTANE | ? unclear | Mechanistic | DGIdb | |
| THONZONIUM BROMIDE | ? unclear | Mechanistic | DGIdb | |
| FENHEXAMID | ? unclear | Mechanistic | DGIdb | |
| LEMILDIPINE | ? unclear | Mechanistic | DGIdb | |
| (R)-BICALUTAMIDE | ? unclear | Mechanistic | DGIdb | |
| MORICIZINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| METIPRANOLOL | ? unclear | Mechanistic | DGIdb | |
| FLUROCHLORIDONE | ? unclear | Mechanistic | DGIdb | |
| PYRIDOSTIGMINE BROMIDE | ? unclear | Mechanistic | DGIdb | |
| FLUTAMIDE | ↓ inhibits | Mechanistic | 154.0 nM (IC50) | DGIdb |
| CHEMBL:CHEMBL224318 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL423081 | ? unclear | Mechanistic | DGIdb | |
| PREDNISOLONE | ? unclear | Mechanistic | 2760.0 nM (Ki) | DGIdb |
| ORBIFLOXACIN | ? unclear | Mechanistic | DGIdb | |
| PROGESTERONE | ? unclear | Mechanistic | 8.5 nM (Ki) | DGIdb |
| FLUDIOXONIL | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1784521 | ? unclear | Mechanistic | DGIdb | |
| FLUMETHASONE | ? unclear | Mechanistic | DGIdb | |
| SERTRALINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MELOXICAM | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL44011 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 994 agents ranked by evidence tier.
CYP17A1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| PACLITAXEL PROTEIN-BOUND | ? unclear | Mechanistic | DGIdb | |
| ORTERONEL | ↓ inhibits | Mechanistic | DGIdb | |
| ENZALUTAMIDE | ? unclear | Mechanistic | DGIdb | |
| GALETERONE | ↓ inhibits | Mechanistic | DGIdb | |
| ABIRATERONE-C6 OXIME | ↓ inhibits | Mechanistic | DGIdb | |
| ABIRATERONE ACETATE | ↓ inhibits | Mechanistic | 17.0 nM (IC50) | DGIdb |
| SEVITERONEL | ? unclear | Mechanistic | DGIdb | |
| LEVOKETOCONAZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| LAPITERONEL | ? unclear | Mechanistic | DGIdb | |
| YXG-158 | ↓ inhibits | Mechanistic | DGIdb | |
| ABIRATERONE | ? unclear | Mechanistic | 4.0 nM (IC50) | Open Targets |
| CHEMBL138580 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL310690 | ↓ inhibits | Mechanistic | 160.0 nM (IC50) | ChEMBL |
| CHEMBL341591 | ↓ inhibits | Mechanistic | 400.0 nM (IC50) | ChEMBL |
| CHEMBL2111948 | ↓ inhibits | Mechanistic | 1520.0 nM (IC50) | ChEMBL |
| CHEMBL3137965 | ↓ inhibits | Mechanistic | 74.0 nM (IC50) | ChEMBL |
| CHEMBL2112781 | ↓ inhibits | Mechanistic | 1250.0 nM (IC50) | ChEMBL |
| CHEMBL357811 | ↓ inhibits | Mechanistic | 27.0 nM (IC50) | ChEMBL |
| CHEMBL2112888 | ↓ inhibits | Mechanistic | 260.0 nM (IC50) | ChEMBL |
| CHEMBL2111947 | ↓ inhibits | Mechanistic | 540.0 nM (IC50) | ChEMBL |
| CHEMBL3137967 | ↓ inhibits | Mechanistic | 5.0 nM (IC50) | ChEMBL |
| CHEMBL2112782 | ↓ inhibits | Mechanistic | 970.0 nM (IC50) | ChEMBL |
| CHEMBL432751 | ↓ inhibits | Mechanistic | 3.0 nM (IC50) | ChEMBL |
| CHEMBL2112772 | ↓ inhibits | Mechanistic | 1520.0 nM (IC50) | ChEMBL |
| CHEMBL310315 | ↓ inhibits | Mechanistic | 13.0 nM (IC50) | ChEMBL |
| CHEMBL82926 | ↓ inhibits | Mechanistic | 47.0 nM (IC50) | ChEMBL |
| CHEMBL2112775 | ↓ inhibits | Mechanistic | 2500.0 nM (IC50) | ChEMBL |
| KETOCONAZOLE | ↓ inhibits | Mechanistic | 740.0 nM (IC50) | ChEMBL |
| CHEMBL3085257 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL2111951 | ↓ inhibits | Mechanistic | 290.0 nM (IC50) | ChEMBL |
| CHEMBL419743 | ↓ inhibits | Mechanistic | 400.0 nM (IC50) | ChEMBL |
| CHEMBL2112522 | ↓ inhibits | Mechanistic | 21.0 nM (IC50) | ChEMBL |
| CHEMBL2112517 | ↓ inhibits | Mechanistic | 42.0 nM (IC50) | ChEMBL |
| CHEMBL2112524 | ↓ inhibits | Mechanistic | 100.0 nM (IC50) | ChEMBL |
| CHEMBL2112526 | ↓ inhibits | Mechanistic | 24.0 nM (IC50) | ChEMBL |
| CHEMBL2112533 | ↓ inhibits | Mechanistic | 400.0 nM (IC50) | ChEMBL |
| CHEMBL2112519 | ↓ inhibits | Mechanistic | 430.0 nM (IC50) | ChEMBL |
| CHEMBL325307 | ↓ inhibits | Mechanistic | 50.0 nM (IC50) | ChEMBL |
| CHEMBL114864 | ↓ inhibits | Mechanistic | 150.0 nM (IC50) | ChEMBL |
| CHEMBL115944 | ↓ inhibits | Mechanistic | 150.0 nM (IC50) | ChEMBL |
Showing top 40 of 124 agents ranked by evidence tier.
CYP19A1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| AZALANSTAT | ↓ inhibits | Mechanistic | 7.6 nM (Ki) | DGIdb |
| NARINGENIN | ? unclear | Mechanistic | DGIdb | |
| TESTOLACTONE | ↓ inhibits | Mechanistic | 35000.0 nM (Ki) | DGIdb |
| ATROPINE | ? unclear | Mechanistic | DGIdb | |
| FADROZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| EXEMESTANE | ↓ inhibits | Mechanistic | DGIdb | |
| AMINOGLUTETHIMIDE | ↓ inhibits | Mechanistic | 600.0 nM (Ki) | DGIdb |
| LIOTHYRONINE | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN | ? unclear | Mechanistic | DGIdb | |
| IBUPROFEN, SODIUM SALT | ? unclear | Mechanistic | DGIdb | |
| LIAROZOLE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1077603 | ? unclear | Mechanistic | DGIdb | |
| AZTREONAM | ? unclear | Mechanistic | DGIdb | |
| GONADOTROPIN-RELEASING HORMONE ANALOG | ? unclear | Mechanistic | DGIdb | |
| ISOPROTERENOL | ? unclear | Mechanistic | DGIdb | |
| CAPTOPRIL | ? unclear | Mechanistic | DGIdb | |
| TAMOXIFEN | ? unclear | Mechanistic | DGIdb | |
| LETROZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| ANASTROZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| ATAMESTANE | ? unclear | Mechanistic | DGIdb | |
| FORMESTANE | ? unclear | Mechanistic | 410.0 nM (IC50) | DGIdb |
| PHYTOESTROGEN | ? unclear | Mechanistic | DGIdb | |
| FADROZOLE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PHENYTOIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| ANABOLIC STEROID | ? unclear | Mechanistic | DGIdb | |
| TESTOSTERONE ENANTHATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL572637 | ? unclear | Mechanistic | DGIdb | |
| ADENOVIRUS VECTOR | ? unclear | Mechanistic | DGIdb | |
| ISOPROPYL ALCOHOL | ? unclear | Mechanistic | DGIdb | |
| BIOFLAVONOID | ? unclear | Mechanistic | DGIdb | |
| ALENDRONATE SODIUM | ? unclear | Mechanistic | DGIdb | |
| CAPECITABINE | ? unclear | Mechanistic | DGIdb | |
| GENISTEIN | ? unclear | Mechanistic | DGIdb | |
| NONSTEROIDAL ANTIINFLAMMATORY DRUG | ? unclear | Mechanistic | DGIdb | |
| ENVIRONMENTAL ESTROGEN | ? unclear | Mechanistic | DGIdb | |
| ANDROSTENEDIONE | ? unclear | Mechanistic | DGIdb | |
| OPIATE | ? unclear | Mechanistic | DGIdb | |
| FLUOROURACIL | ? unclear | Mechanistic | DGIdb | |
| NORENDOXIFEN | ↓ inhibits | Mechanistic | DGIdb | |
| ENDOXIFEN | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 187 agents ranked by evidence tier.
FSHR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| FOLLICLE STIMULATING HORMONE | ? unclear | Mechanistic | DGIdb | |
| CORIFOLLITROPIN ALFA | ↑ activates | Mechanistic | DGIdb | |
| UROFOLLITROPIN | ↑ activates | Mechanistic | DGIdb | |
| FOLLITROPIN | ↑ activates | Mechanistic | DGIdb | |
| [125I]FSH (HUMAN) | ↑ activates | Mechanistic | DGIdb | |
| FSH DEGLYCOSYLATED Α/Β | ↓ inhibits | Mechanistic | DGIdb | |
| SURAMIN | ? unclear | Mechanistic | DGIdb | |
| CHORIONIC GONADOTROPIN | ? unclear | Mechanistic | DGIdb | |
| FOLLITROPIN ALFA | ↑ activates | Mechanistic | DGIdb | |
| CHORIOGONADOTROPIN ALFA | ? unclear | Mechanistic | DGIdb | |
| THYROTROPIN ALFA | ? unclear | Mechanistic | DGIdb | |
| FOLLITROPIN BETA | ↑ activates | Mechanistic | DGIdb | |
| FOLLITROPIN DELTA | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL50556 | ↑ activates | Mechanistic | 260.0 nM (EC50) | ChEMBL |
| CHEMBL417173 | ↑ activates | Mechanistic | 2500.0 nM (EC50) | ChEMBL |
| CHEMBL47120 | ↑ activates | Mechanistic | 3900.0 nM (EC50) | ChEMBL |
| CHEMBL50278 | ↑ activates | Mechanistic | 3000.0 nM (EC50) | ChEMBL |
| CHEMBL279759 | ↑ activates | Mechanistic | 25.0 nM (EC50) | ChEMBL |
| CHEMBL296449 | ↑ activates | Mechanistic | 68.0 nM (EC50) | ChEMBL |
| CHEMBL49308 | ↑ activates | Mechanistic | 120.0 nM (EC50) | ChEMBL |
| CHEMBL45976 | ↑ activates | Mechanistic | 400.0 nM (EC50) | ChEMBL |
| CHEMBL46216 | ↑ activates | Mechanistic | 9.7 nM (EC50) | ChEMBL |
| CHEMBL47838 | ↑ activates | Mechanistic | 900.0 nM (EC50) | ChEMBL |
| CHEMBL48375 | ↑ activates | Mechanistic | 8.9 nM (EC50) | ChEMBL |
| CHEMBL47953 | ↑ activates | Mechanistic | 1.8 nM (EC50) | ChEMBL |
| CHEMBL295895 | ↑ activates | Mechanistic | 1.2 nM (EC50) | ChEMBL |
| CHEMBL417003 | ↑ activates | Mechanistic | 1200.0 nM (EC50) | ChEMBL |
| CHEMBL47420 | ↑ activates | Mechanistic | 3300.0 nM (EC50) | ChEMBL |
| CHEMBL300022 | ↑ activates | Mechanistic | 3.0 nM (EC50) | ChEMBL |
| CHEMBL49608 | ↑ activates | Mechanistic | 7.2 nM (EC50) | ChEMBL |
| CHEMBL45782 | ↑ activates | Mechanistic | 5000.0 nM (EC50) | ChEMBL |
| CHEMBL47059 | ↑ activates | Mechanistic | 14.0 nM (EC50) | ChEMBL |
| CHEMBL48030 | ↑ activates | Mechanistic | 3.6 nM (EC50) | ChEMBL |
| CHEMBL49540 | ↑ activates | Mechanistic | 1600.0 nM (EC50) | ChEMBL |
| CHEMBL45770 | ↑ activates | Mechanistic | 1.7 nM (EC50) | ChEMBL |
| CHEMBL433263 | ↑ activates | Mechanistic | 2.7 nM (EC50) | ChEMBL |
| CHEMBL47500 | ↑ activates | Mechanistic | 100.0 nM (EC50) | ChEMBL |
| CHEMBL44663 | ↑ activates | Mechanistic | 150.0 nM (EC50) | ChEMBL |
| CHEMBL298686 | ↑ activates | Mechanistic | 2300.0 nM (EC50) | ChEMBL |
| CHEMBL432883 | ↑ activates | Mechanistic | 9000.0 nM (EC50) | ChEMBL |
Showing top 40 of 108 agents ranked by evidence tier.
GLP1R
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LINAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| FRONIGLUTIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL576809 | ? unclear | Mechanistic | DGIdb | |
| 2-METHOXYESTRADIOL | ? unclear | Mechanistic | DGIdb | |
| SURVODUTIDE | ↑ activates | Mechanistic | DGIdb | |
| LIRAGLUTIDE | ↑ activates | Mechanistic | DGIdb | |
| GLUCAGON-LIKE PEPTIDE 1-(7-36) AMIDE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL530609 | ? unclear | Mechanistic | DGIdb | |
| PRAMLINTIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL580076 | ? unclear | Mechanistic | DGIdb | |
| PEGAPAMODUTIDE | ↑ activates | Mechanistic | DGIdb | |
| TRICLABENDAZOLE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL597244 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL600734 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1422704 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1390716 | ? unclear | Mechanistic | DGIdb | |
| AMORFRUTIN A | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL317115 | ? unclear | Mechanistic | DGIdb | |
| FENBENDAZOLE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL585444 | ? unclear | Mechanistic | DGIdb | |
| MITONAFIDE | ? unclear | Mechanistic | DGIdb | |
| HOMIDIUM BROMIDE | ? unclear | Mechanistic | DGIdb | |
| GLUCAGON-LIKE PEPTIDE 1-(7-37) | ↑ activates | Mechanistic | DGIdb | |
| DANUGLIPRON | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1543865 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL532452 | ? unclear | Mechanistic | DGIdb | |
| AVEXITIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL548286 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1270168 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL591834 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL581152 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL605708 | ? unclear | Mechanistic | DGIdb | |
| LASALOCID A SODIUM | ? unclear | Mechanistic | DGIdb | |
| SAXAGLIPTIN ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL86464 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1509103 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL261693 | ? unclear | Mechanistic | DGIdb | |
| ALBUTEROL SULFATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1569494 | ? unclear | Mechanistic | DGIdb | |
| GLUTAZUMAB | ↑ activates | Mechanistic | DGIdb |
Showing top 40 of 316 agents ranked by evidence tier.
INSR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LINSITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| GW441756X | ? unclear | Mechanistic | DGIdb | |
| INSULIN GLARGINE | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ASPART PROTAMINE, HUMAN | ↑ activates | Mechanistic | DGIdb | |
| INSULIN, ISOPHANE | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ASPART PROTAMINE RECOMBINANT | ↑ activates | Mechanistic | DGIdb | |
| MITOGLITAZONE | ? unclear | Mechanistic | DGIdb | |
| HESPERADIN | ↓ inhibits | Mechanistic | DGIdb | |
| INSULIN, NEUTRAL | ↑ activates | Mechanistic | DGIdb | |
| INSULIN TREGOPIL | ↑ activates | Mechanistic | DGIdb | |
| AGT-182 | ? unclear | Mechanistic | DGIdb | |
| LINIFANIB | ? unclear | Mechanistic | DGIdb | |
| TOPIRAMATE | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ↑ activates | Mechanistic | DGIdb | |
| SP-600125 | ? unclear | Mechanistic | DGIdb | |
| NVP-TAE684 | ? unclear | Mechanistic | DGIdb | |
| INSULIN HUMAN ZINC | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ICODEC | ↑ activates | Mechanistic | DGIdb | |
| CERITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| BMS-536924 | ↓ inhibits | Mechanistic | DGIdb | |
| CYC-116 | ? unclear | Mechanistic | DGIdb | |
| INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN | ↑ activates | Mechanistic | DGIdb | |
| COMPOUND 15 [PMID: 24900237] | ↓ inhibits | Mechanistic | DGIdb | |
| INSULIN, PORCINE | ? unclear | Mechanistic | DGIdb | |
| BMS-754807 | ↓ inhibits | Mechanistic | DGIdb | |
| TESOFENSINE | ? unclear | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| CENISERTIB | ? unclear | Mechanistic | DGIdb | |
| INSULIN HUMAN | ↑ activates | Mechanistic | DGIdb | |
| NVP-TAE 226 | ↓ inhibits | Mechanistic | DGIdb | |
| INSULIN PURIFIED PORK | ↑ activates | Mechanistic | DGIdb | |
| FLUOROURACIL | ? unclear | Mechanistic | DGIdb | |
| INSULIN SUSP ISOPHANE BEEF | ↑ activates | Mechanistic | DGIdb | |
| RECOMBINANT HUMAN KALLIKREIN-1 | ? unclear | Mechanistic | DGIdb | |
| INSULIN LISPRO | ↑ activates | Mechanistic | DGIdb | |
| GÖ 6976 | ? unclear | Mechanistic | DGIdb | |
| MYRICETIN | ↓ inhibits | Mechanistic | 2600.0 nM (Ki) | DGIdb |
| INSULIN ZINC SUSP RECOMBINANT HUMAN | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC, EXTENDED | ↑ activates | Mechanistic | DGIdb | |
| TAMATINIB | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 245 agents ranked by evidence tier.
LHCGR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHORIONIC GONADOTROPIN | ↑ activates | Mechanistic | DGIdb | |
| LUTROPIN ALFA | ↑ activates | Mechanistic | DGIdb | |
| CHORIOGONADOTROPIN ALFA | ? unclear | Mechanistic | DGIdb | |
| HCG | ↑ activates | Mechanistic | DGIdb | |
| UROFOLLITROPIN | ↑ activates | Mechanistic | DGIdb | |
| RELUGOLIX | ? unclear | Mechanistic | DGIdb | |
| [125I]LH | ↑ activates | Mechanistic | DGIdb | |
| LH (MENOTROPINS) | ↑ activates | Mechanistic | DGIdb | |
| GTX-758 | ? unclear | Mechanistic | DGIdb | |
| GONADOTROPIN, CHORIONIC | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL448753 | ? unclear | Mechanistic | DGIdb | |
| CTP-37-DT VACCINE | ? unclear | Mechanistic | DGIdb | |
| [125I]CHORIONIC GONADOTROPIN (HUMAN) | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL505670 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL429095 | ? unclear | Mechanistic | DGIdb | |
| FOLLICLE STIMULATING HORMONE | ? unclear | Mechanistic | DGIdb | |
| GOSERELIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL378091 | ↑ activates | Mechanistic | 1900.0 nM (EC50) | ChEMBL |
| CHEMBL212815 | ↑ activates | Mechanistic | 1200.0 nM (EC50) | ChEMBL |
| CHEMBL211129 | ↑ activates | Mechanistic | 1500.0 nM (EC50) | ChEMBL |
| CHEMBL377769 | ↑ activates | Mechanistic | 800.0 nM (EC50) | ChEMBL |
| CHEMBL377399 | ↑ activates | Mechanistic | 800.0 nM (EC50) | ChEMBL |
| CHEMBL211871 | ↑ activates | Mechanistic | 1100.0 nM (EC50) | ChEMBL |
| CHEMBL211405 | ↑ activates | Mechanistic | 300.0 nM (EC50) | ChEMBL |
| CHEMBL246321 | ↓ inhibits | Mechanistic | 0.311 nM (Ki) | ChEMBL |
| CHEMBL429108 | ↑ activates | Mechanistic | 80.0 nM (EC50) | ChEMBL |
| CHEMBL393847 | ↑ activates | Mechanistic | 190.0 nM (EC50) | ChEMBL |
| CHEMBL439392 | ↑ activates | Mechanistic | 150.0 nM (EC50) | ChEMBL |
| CHEMBL247700 | ↑ activates | Mechanistic | 170.0 nM (EC50) | ChEMBL |
| CHEMBL269261 | ↑ activates | Mechanistic | 12100.0 nM (EC50) | ChEMBL |
| CHEMBL247945 | ↑ activates | Mechanistic | 500.0 nM (EC50) | ChEMBL |
| CHEMBL397316 | ↑ activates | Mechanistic | 250.0 nM (EC50) | ChEMBL |
| CHEMBL245663 | ↑ activates | Mechanistic | 2300.0 nM (EC50) | ChEMBL |
| CHEMBL474041 | ↓ inhibits | Mechanistic | 2300.0 nM (IC50) | ChEMBL |
| CHEMBL1651721 | ↑ activates | Mechanistic | 1.0 nM (EC50) | ChEMBL |
| CHEMBL1651723 | ↑ activates | Mechanistic | 10.0 nM (EC50) | ChEMBL |
| CHEMBL1651823 | ↑ activates | Mechanistic | 27.0 nM (EC50) | ChEMBL |
| CHEMBL1651824 | ↑ activates | Mechanistic | 43.0 nM (EC50) | ChEMBL |
| CHEMBL1651825 | ↑ activates | Mechanistic | 61.0 nM (EC50) | ChEMBL |
| CHEMBL1651826 | ↑ activates | Mechanistic | 55.0 nM (EC50) | ChEMBL |
Showing top 40 of 78 agents ranked by evidence tier.
PPARG
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| GANCAONIN L | ? unclear | Mechanistic | DGIdb | |
| MITOGLITAZONE | ? unclear | Mechanistic | DGIdb | |
| BADGE | ↓ inhibits | Mechanistic | DGIdb | |
| OLSALAZINE SODIUM | ↑ activates | Mechanistic | DGIdb | |
| CELECOXIB | ? unclear | Mechanistic | DGIdb | |
| LY-510929 | ↑ activates | Mechanistic | 10.0 nM (IC50) | DGIdb |
| TROGLITAZONE | ↑ activates | Mechanistic | 302.0 nM (Ki) | DGIdb |
| BENZBROMARONE | ? unclear | Mechanistic | DGIdb | |
| APIGENIN | ? unclear | Mechanistic | DGIdb | |
| CHIGLITAZAR | ↑ activates | Mechanistic | DGIdb | |
| LEVOTHYROXINE | ? unclear | Mechanistic | DGIdb | |
| NALED | ? unclear | Mechanistic | DGIdb | |
| CLX-0921 | ? unclear | Mechanistic | DGIdb | |
| MBX-2044 | ~ modulates | Mechanistic | DGIdb | |
| DICHLOROPHEN | ? unclear | Mechanistic | DGIdb | |
| LANIFIBRANOR | ↑ activates | Mechanistic | DGIdb | |
| TRIFLOXYSTROBIN | ? unclear | Mechanistic | DGIdb | |
| PROCHLORAZ | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL599165 | ? unclear | Mechanistic | DGIdb | |
| NAVEGLITAZAR | ↑ activates | Mechanistic | DGIdb | |
| RAGAGLITAZAR | ↑ activates | Mechanistic | DGIdb | |
| ALEGLITAZAR | ↑ activates | Mechanistic | DGIdb | |
| TREPROSTINIL | ? unclear | Mechanistic | DGIdb | |
| GW7845 | ↑ activates | Mechanistic | DGIdb | |
| METHOTREXATE | ? unclear | Mechanistic | DGIdb | |
| FENOFIBRIC ACID | ? unclear | Mechanistic | DGIdb | |
| ATX08-001 | ~ modulates | Mechanistic | DGIdb | |
| JB991 | ? unclear | Mechanistic | DGIdb | |
| AD-5061 | ↑ activates | Mechanistic | DGIdb | |
| GW409544 | ↑ activates | Mechanistic | DGIdb | |
| [125I]SB-236636 | ↑ activates | Mechanistic | DGIdb | |
| ROSIGLITAZONE MALEATE | ↑ activates | Mechanistic | DGIdb | |
| RIVOGLITAZONE | ↑ activates | Mechanistic | DGIdb | |
| MESALAMINE | ↑ activates | Mechanistic | DGIdb | |
| BALSALAZIDE DISODIUM | ↑ activates | Mechanistic | DGIdb | |
| 2-PHENYLPHENOL | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL184450 | ? unclear | Mechanistic | DGIdb | |
| ABIETIC ACID | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2208196 | ? unclear | Mechanistic | DGIdb | |
| ASPIRIN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 274 agents ranked by evidence tier.
PRKAA1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CENISERTIB | ? unclear | Mechanistic | DGIdb | |
| SIROLIMUS | ? unclear | Mechanistic | DGIdb | |
| JNJ-7706621 | ? unclear | Mechanistic | 1700.0 nM (Kd) | DGIdb |
| SAPONARIN | ? unclear | Mechanistic | DGIdb | |
| TYROSINE KINASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| METFORMIN HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| ENTRECTINIB | ? unclear | Mechanistic | 251.19 nM (Ki) | DGIdb |
| PHENFORMIN | ? unclear | Mechanistic | DGIdb | |
| PALBOCICLIB | ? unclear | Mechanistic | DGIdb | |
| LY2090314 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1997335 | ? unclear | Mechanistic | DGIdb | |
| TETRADECANOYLPHORBOL ACETATE | ? unclear | Mechanistic | DGIdb | |
| DOVITINIB | ? unclear | Mechanistic | 520.0 nM (Kd) | DGIdb |
| CHEMOPREVENTIVE AGENT | ? unclear | Mechanistic | DGIdb | |
| METFORMIN | ? unclear | Mechanistic | DGIdb | |
| SOTRASTAURIN | ? unclear | Mechanistic | 630.96 nM (Ki) | DGIdb |
| CHEMBL:CHEMBL587615 | ? unclear | Mechanistic | DGIdb | |
| NVP-TAE684 | ? unclear | Mechanistic | DGIdb | |
| PD166285 | ? unclear | Mechanistic | DGIdb | |
| LEVOTHYROXINE SODIUM | ? unclear | Mechanistic | DGIdb | |
| TOZASERTIB | ? unclear | Mechanistic | 1100.0 nM (Kd) | DGIdb |
| HESPERADIN | ↓ inhibits | Mechanistic | 19.0 nM (Kd) | DGIdb |
| ACADESINE | ↑ activates | Mechanistic | DGIdb | |
| ADENOSINE DEAMINASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| PENTOSTATIN | ? unclear | Mechanistic | DGIdb | |
| GW441756X | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL379975 | ? unclear | Mechanistic | DGIdb | |
| ILORASERTIB | ? unclear | Mechanistic | DGIdb | |
| CYC-116 | ? unclear | Mechanistic | 501.19 nM (Ki) | DGIdb |
| RG-1530 | ? unclear | Mechanistic | DGIdb | |
| PF-562271 | ? unclear | Mechanistic | DGIdb | |
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| SUNITINIB | ↓ inhibits | Mechanistic | 52.0 nM (Kd) | ChEMBL |
| ALVOCIDIB | ↓ inhibits | Mechanistic | 6600.0 nM (Kd) | ChEMBL |
| STAUROSPORINE | ↓ inhibits | Mechanistic | 9.0 nM (Kd) | ChEMBL |
| VANDETANIB | ↓ inhibits | Mechanistic | 10000.0 nM (Kd) | ChEMBL |
| AST-487 | ↓ inhibits | Mechanistic | 1400.0 nM (Kd) | ChEMBL |
| RAF-265 | ↓ inhibits | Mechanistic | 4500.0 nM (Kd) | ChEMBL |
| MIDOSTAURIN | ↓ inhibits | Mechanistic | 180.0 nM (Kd) | ChEMBL |
| SU-014813 | ↓ inhibits | Mechanistic | 100.0 nM (Kd) | ChEMBL |
Showing top 40 of 204 agents ranked by evidence tier.
SHBG
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHEMBL:CHEMBL464631 | ? unclear | Mechanistic | DGIdb | |
| NORGESTREL | ? unclear | Mechanistic | 1.23 nM (Kd) | DGIdb |
| SOMATROPIN (RECOMBINANT DNA ORIGIN) | ? unclear | Mechanistic | DGIdb | |
| BUSULFAN | ? unclear | Mechanistic | DGIdb | |
| DROLOXIFENE | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| ANTICONVULSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| ADJUVANT | ? unclear | Mechanistic | DGIdb | |
| LISINOPRIL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| STANOLONE | ↓ inhibits | Mechanistic | 3.8 nM (IC50) | ChEMBL |
| CHEMBL194392 | ↓ inhibits | Mechanistic | 22400.0 nM (IC50) | ChEMBL |
| CHEMBL193200 | ↓ inhibits | Mechanistic | 13600.0 nM (IC50) | ChEMBL |
| CHEMBL218958 | ↓ inhibits | Mechanistic | 48230.0 nM (IC50) | ChEMBL |
| CHEMBL216530 | ↓ inhibits | Mechanistic | 11140.0 nM (IC50) | ChEMBL |
| CHEMBL216660 | ↓ inhibits | Mechanistic | 10350.0 nM (IC50) | ChEMBL |
| CHEMBL386857 | ↓ inhibits | Mechanistic | 950.0 nM (IC50) | ChEMBL |
| ESTRADIOL | ↓ inhibits | Mechanistic | 50.0 nM (IC50) | ChEMBL |
| TESTOSTERONE | ↓ inhibits | Mechanistic | 14.0 nM (IC50) | ChEMBL |
| CHEMBL265939 | ↓ inhibits | Mechanistic | 2187.76 nM (Kd) | ChEMBL |
| NARINGENIN | ↓ inhibits | Mechanistic | 954.99 nM (Kd) | ChEMBL |
| CHEMBL265940 | ↓ inhibits | Mechanistic | 831.76 nM (Kd) | ChEMBL |
| CHEMBL259383 | ↓ inhibits | Mechanistic | 588.84 nM (Kd) | ChEMBL |
| CHEMBL259997 | ↓ inhibits | Mechanistic | 2187.76 nM (Kd) | ChEMBL |
| CHEMBL406776 | ↓ inhibits | Mechanistic | 407.38 nM (Kd) | ChEMBL |
| CHEMBL259384 | ↓ inhibits | Mechanistic | 107.15 nM (Kd) | ChEMBL |
| GENISTEIN | ↓ inhibits | Mechanistic | 39810.72 nM (Kd) | ChEMBL |
| CHEMBL408649 | ↓ inhibits | Mechanistic | 28840.32 nM (Kd) | ChEMBL |
| CHEMBL265178 | ↓ inhibits | Mechanistic | 10964.78 nM (Kd) | ChEMBL |
| ALDOSTERONE | ↓ inhibits | Mechanistic | 4786.3 nM (Kd) | ChEMBL |
| CHEMBL408778 | ↓ inhibits | Mechanistic | 2454.71 nM (Kd) | ChEMBL |
| CHEMBL259327 | ↓ inhibits | Mechanistic | 2137.96 nM (Kd) | ChEMBL |
| 4-NONYLPHENOL | ↓ inhibits | Mechanistic | 1202.26 nM (Kd) | ChEMBL |
| CHEMBL409022 | ↓ inhibits | Mechanistic | 1148.15 nM (Kd) | ChEMBL |
| ESTRADIOL BENZOATE | ↓ inhibits | Mechanistic | 1148.15 nM (Kd) | ChEMBL |
| ETIOCHOLANOLONE | ↓ inhibits | Mechanistic | 707.95 nM (Kd) | ChEMBL |
| HYDROCORTISONE | ↓ inhibits | Mechanistic | 630.96 nM (Kd) | ChEMBL |
| MEDROXYPROGESTERONE ACETATE | ↓ inhibits | Mechanistic | 630.96 nM (Kd) | ChEMBL |
| NANDROLONE | ↓ inhibits | Mechanistic | 501.19 nM (Kd) | ChEMBL |
| CORTICOSTERONE | ↓ inhibits | Mechanistic | 457.09 nM (Kd) | ChEMBL |
Showing top 40 of 107 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is PCOS (Polycystic Ovary Syndrome): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
This study will look at whether a reduced-calorie Mediterranean-style eating plan, together with a synbiotic supplement, can improve health measures and quality of life in women who have polycystic ovary syndrome (PCOS) and are overweight or have obesity. Participants will be assigned by chance (lik...
To determine if Inositol, a dietary supplement, will improve ovarian and adrenal androgen excess in women with Polycystic Ovarian Syndrome(PCOS).
The study aims to evaluate the effects of combination of metformin with NAC in PCOS on biochemical and hormonal parameters.
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.
Polycystic ovary syndrome (PCOS) is a common endocrine disorder frequently associated with obesity, insulin resistance (IR), and metabolic dysfunction. Although lifestyle modification is recommended as first-line therapy, the optimal dietary approach for women with PCOS remains uncertain. This rando...
Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders affecting women of reproductive age. Its prevalence varies considerably according to the population studied and the diagnostic criteria applied. A recent global systematic review and meta-analysis estimated ...
This study will compare the effectiveness of clomiphene citrate alone with clomiphene citrate combined with metformin for treating anovulation and infertility in women with polycystic ovary syndrome (PCOS). Women with PCOS who have difficulty becoming pregnant because they do not ovulate regularly w...
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that is frequently associated with metabolic features, including obesity. Improvement of metabolic manifestations helps in the control of symptoms, including subfertility. Metformin has been commonly used to decrease insulin resistance ...
The aim of this study is to see the associations of metabolic responses of metformin with single nucleotide polymorphisms (SNPs) (rs628031 and rs2282143) of solute carrier family 22 member 1 (SLC22A1) gene in women with polycystic ovary syndrome (PCOS). This prospective clinical study will be conduc...
Polycystic ovary syndrome (PCOS),is a complex neuro-endocrine disorder affecting approximately 5% to 10% of women in reproductive age.Inositols are considered insulin sensitizers, as they modulate the members of insulin signaling pathways.Thiss study compares between the effect of inositol and metfo...
A prospective study to determine the metabolic effects of the contraceptive vaginal ring among overweight and obese women with polycystic ovary syndrome (PCOS). We will recruit a total of 40 participants and study use of the vaginal ring over a 4-month period.
The goal of this clinical trial is to learn the efficacy of Mazdutide in treating obese female adults diagnosed with polycystic ovary syndrome (PCOS). The main question it aims to answer is: Does Mazdutide lower the free androgen index (FAI) in obese female adults with PCOS? Participants will take M...
This research study aims to investigate the effect of adding Alpha lipoic acid (ALA) supplement to letrozole treatment in infertile women with polycystic ovary syndrome (PCOS). The study will include 150 PCOS participants seeking fertility treatment. They will be randomly divided into two groups - c...
Polycystic ovary syndrome (PCOS) is a common condition associated with metabolic abnormalities, including insulin resistance, impaired glucose regulation, and abnormal lipid levels. Metformin is commonly used to improve metabolic outcomes in women with PCOS, while lifestyle modification and behavior...
The Study aims to determine the proposed positive influence of Sitagliptin in manipulating hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary syndrome and subsequent infertility
Agents Found By Disease-Level Search
Searched directly from “PCOS (Polycystic Ovary Syndrome)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 11-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
42 agents shown (approved or with trial evidence) — 33 not found by the gene-target search above.
Metformin
Letrozole
leuprolide acetate
hCG
Cetrorelix acetateNOT in gene-target list
Alpha lipoic acidNOT in gene-target list
Vitamin D3NOT in gene-target list
Calcium CarbonateNOT in gene-target list
Cinnamon Cap 500 MGNOT in gene-target list
OCP + MetforminNOT in gene-target list
Anthropometric and physical examinationNOT in gene-target list
Indirect calorimetry, accelerometer and seven-day dietary recallNOT in gene-target list
Biochemical, hormonal and metabolic phenotypingNOT in gene-target list
Sonographic studiesNOT in gene-target list
Cardiovascular autonomic function studiesNOT in gene-target list
Oral smear and feces specimenNOT in gene-target list
ECoFamNOT in gene-target list
Escitalopram 20 mgNOT in gene-target list
Pioglitazone 30 Mg Oral TabletNOT in gene-target list
metformin 500 mg thrice dailyNOT in gene-target list
degarelix (long acting GnRH antagonist)NOT in gene-target list
cetrorelix 0.25mgNOT in gene-target list
spironolactone
SIMVASTATIN
Mazdutide
Adolescent PCOS group receiving oral contraceptivesNOT in gene-target list
Human Chorionic Gonadotropin (hCG)NOT in gene-target list
GonadotropinsNOT in gene-target list
GNRH-A TriptorelinNOT in gene-target list
GnRH antagonistNOT in gene-target list
Resveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day)NOT in gene-target list
Metformin (500 mg Twice a day), Pioglitazone (15 mg Twice a day)NOT in gene-target list
liraglutide
Clomifene citrate ( clomid 50 mg )NOT in gene-target list
AmlodipineNOT in gene-target list
Myo-inositolNOT in gene-target list
Progesterone
GnRH antagonist (Cetrorelix)NOT in gene-target list
Letrozole 2.5mgNOT in gene-target list
VipdometNOT in gene-target list
IncresyncNOT in gene-target list
recombinant human chorionic gonadotropinNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.